肿瘤病理生物学与肿瘤治疗对策.pptVIP

* 美罗华（MabThera， rituximab） * MAB-0062　　ER 福尔马林固定，石蜡包埋。乳腺导 管内癌，ER阳性定位胞核， UltraSensitiveTM SP（PAN）试 剂盒，DAB显色，苏木素复染。 SP X 200 MAB-0236　　PR 福尔马林固定，石蜡包埋。乳腺浸润 性导管癌，PR阳性定位胞核， UltraSensitiveTM SP（PAN）试剂 盒，DAB显色，苏木素复染。 SP X 100 * Immunohistochemical staining using the EGFR pharmDx kit showing negative (a), 1+ (b), 2+ (c) and 3+ (d) membrane labeling for EGFR in four different colorectal carcinomas. 问题：什么时候EGFR靶点治疗可被批准用于临床？回答：最先被批准的3个药物为：ZD1839（Iressa），OSI－774（erlotinib）和IMC－C225（cetuximab）。前两个是小分子的酪氨酸激酶抑制剂，最后一个为针对EGFR细胞膜外结构域的单克隆抗体。作为NSCLC的一线治疗方案，两个Ⅲ期临床试验已在进行。最近，美国FDA已批准ZD1839单药治疗作为NSCLC的三线治疗方案。在日本，厚生省（MOHF）已批准ZD1839作为复发的晚期NSCLC的两线治疗方案。IDEAL－1的最终结果和IDEAL－2的最初结果已在2002年美国临床肿瘤协会（ASCO）上报告。2002年2月末，开始了IMC－C225治疗头颈部肿瘤的Ⅲ期临床试验。其用于晚期直肠结肠癌的Ⅲ期临床试验也在进行。但2002年2月26日的FDA对审批时间进行了调整。OSI－774在治疗NSCLC及胰腺癌领域中进行了四个Ⅲ期临床试验，但要过一段时间才会出来结果。 * GIST showing strong cytoplasmic stainingfor CD117. 格列卫（Glivec，STI 571） * HER2 Status in Breast Cancer 赫赛汀（Herceptin） * An oxygen molecule is 0.29 nanometers in diameter and a nitrogen molecule is only slightly bigger: 0.31 nanometers. * * * * 扫描范围为3μm时,人成纤维细胞膜(左)与人成纤维细胞癌变细胞膜(右)平面与立体结构 * There are about 75 trillion cells in the human body and?excluding the unique physiology of red blood cells, all cells need to 1) communicate, 2) regulate, 3) protect, and 4) be nourished as self controlling factories.? Although they have an exquisitely complex set of internal instructions (the DNA) for self repair,?the cells communicate their needs through neighboring and assisting cells?and agents. * Drug Development OverviewThe Drug Development Office (DDO) at Cancer Research UK is a dedicated team with broad experience in the development of oncology therapeutics. The DDO manages and executes drug development programmes and is responsible for designing, conducting and monitoring high quality, ethical, early phase clinical trials through its collaborations with world-class clinical centres. By working closely with leading UK scientists and clinicians, the DDO offers a